Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesRepurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients
Davis MW, McManus D, Koff A, Jaszczur GR, Malinis M, Dela Cruz C, Britto CJ, Price C, Azmy V, Kaman K, Gaston D, Early K, DeWitt M, Song JS, Ortiz C, Juthani-Mehta M, Topal JE. Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients. Infection Control And Hospital Epidemiology 2020, 41: 1335-1337. PMID: 32507113, PMCID: PMC7308631, DOI: 10.1017/ice.2020.281.Peer-Reviewed Original Research